Racial difference of mutational signature in hepatocellular carcinoma

Abstract

Aim: Previous studies have demonstrated the racial disparities of new incidence and mortality rate of hepatocellular carcinoma (HCC) patients, but the racial differences in the tumor characteristics causing these disparities remain unclear.

Methods: We collected genomic mutation profile of 589 HCC patients, including Asian-Korea (n = 231), Asian-TCGA (n = 156), White-TCGA (n = 176), and Black-TCGA (n = 16). We applied a non-negative factorized matrix algorithm to decipher the mutational signatures of HCC patients, compared racial differences of mutational signature, performed molecular subtyping analysis of HCC patients based on their composition of mutational signatures, and evaluated their influence on clinical outcome.

Results: Asian patients showed a significantly higher level of SBS96F-aristolochic acid exposure signature related to the widespread usage of Chinese herbs in East Asia, and they also showed higher SBS96B-MMR at T > C mutations but lower SBS96D-MMR at C > T mutations than White patients, suggesting the heterogeneous mechanisms related to defective DNA mismatch repair across races. Asian-Korea patients showed a significantly higher SBS96C-tobacco chewing and aflatoxin exposure than the other three populations, indicating the higher levels of aflatoxin contamination in food and environment in this area. The SBS96G-Unclear signature was also observed to be significantly higher in Asian-Korea patients, and their dominated subgroup patients showed better prognosis for both disease-free and overall survival probability.

Conclusion: Our study found racial differences of mutational signatures to be associated with differences in diverse genetic backgrounds and environmental factors, which might help guide the personalized treatment of HCC patients.

Keywords

Mutational signatures / aflatox in exposure / tobacco chewing / aristolochic acid exposure

References

[1] Villanueva A.Hepatocellular carcinoma.N Engl J Med2019;380:1450-62

[2] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2018;68:394-424

[3] Akinyemiju T,Ahmed M.Global Burden of Disease Liver Cancer CollaborationThe burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015.JAMA Oncol2017;3:1683-91 PMCID:PMC5824275

[4] Guichard C,Imbeaud S.Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.Nat Genet2012;44:694-8 PMCID:PMC3819251

[5] Llovet JM,Pikarsky E.Hepatocellular carcinoma.Nat Rev Dis Primers2016;2:16018

[6] Marquardt JU,Andersen JB.Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits.J Hepatol2014;60:346-53 PMCID:PMC3943679

[7] Schulze K,Letouzé E.Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.Nat Genet2015;47:505-11 PMCID:PMC4587544

[8] Zucman-Rossi J,Nault JC.Genetic landscape and biomarkers of hepatocellular carcinoma.Gastroenterology2015;149:1226-39.e4

[9] Nault JC,Caruso S.Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma.Hepatology2020;71:164-82

[10] Müller M,Nault JC.The landscape of gene mutations in cirrhosis and hepatocellular carcinoma.J Hepatol2020;72:990-1002

[11] Ahn SM,Shim JH.Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.Hepatology2014;60:1972-82

[12] Bailey MH,Porta-Pardo E.MC3 Working GroupCancer Genome Atlas Research NetworkComprehensive characterization of cancer driver genes and mutations.Cell2018;173:371-85.e18 PMCID:PMC6029450

[13] Stratton MR,Futreal PA.The cancer genome.Nature2009;458:719-24 PMCID:PMC2821689

[14] Alexandrov LB,Haradhvala NJ.PCAWG Mutational Signatures Working GroupPCAWG ConsortiumThe repertoire of mutational signatures in human cancer.Nature2020;578:94-101 PMCID:PMC7054213

[15] Alexandrov LB,Wedge DC,Stratton MR.Deciphering signatures of mutational processes operative in human cancer.Cell Rep2013;3:246-59 PMCID:PMC3588146

[16] Alexandrov LB,Wedge DC.Australian Pancreatic Cancer Genome InitiativeICGC Breast Cancer ConsortiumICGC MMML-Seq ConsortiumICGC PedBrainSignatures of mutational processes in human cancer.Nature2013;500:415-21 PMCID:PMC3776390

[17] Alexandrov LB.Mutational signatures: the patterns of somatic mutations hidden in cancer genomes.Curr Opin Genet Dev2014;24:52-60 PMCID:PMC3990474

[18] Ng AWT,Huang MN.Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia.Sci Transl Med2017;9:eaan6446

[19] Lu ZN,Zhao LN.The mutational features of aristolochic acid-induced mouse and human liver cancers.Hepatology2020;71:929-42

[20] Mei N,Phillips DH,Chen T.DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liver.Mutat Res2006;602:83-91 PMCID:PMC6370021

[21] Hu SL,Chan K.Studies on the toxicity of Aristolochia manshuriensis (Guanmuton).Toxicology2004;198:195-201

[22] Chang SY,Sidorenko VS.Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity.JCI Insight2017;2:95978 PMCID:PMC5752374

[23] Chalabi M,Dijkstra KK.Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.Nat Med2020;26:566-76

[24] Overman MJ,Wong KYM.Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.J Clin Oncol2018;36:773-9

[25] Overman MJ,Leach JL.Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.Lancet Oncol2017;18:1182-91 PMCID:PMC6207072